Claims for Patent: 9,233,107

Summary for Patent: 9,233,107

Title:	Compositions and methods for the treatment of progressive multifocal leukoencephalopathy (PML)
Abstract:	The invention relates to compositions, methods, and kits for treating subjects infected by or at risk of infection with a DNA virus (e.g., a JC Virus or a BK virus). Aspects of the invention are useful to prevent or treat DNA virus associated conditions (e.g., PML) in subjects that are immunocompromised. Compositions are provided that inhibit intracellular replication of DNA viruses.
Inventor(s):	Gorelik; Leonid (Quincy, MA), Brickelmaier; Margot (Boxford, MA), Lugovskoy; Alexey (Woburn, MA)
Assignee:	Biogen MA Inc. (Cambridge, MA)
Application Number:	12/678,011
Patent Claims:	1. A method of inhibiting polyomavirus replication in a subject, the method comprising administering a composition to a subject suspected of having a polyomavirus infection, wherein the composition comprises fusidic acid in an amount sufficient to inhibit polyomavirus replication in the subject. 2. The method of claim 1, wherein the polyomavirus is JC virus. 3. The method of claim 1, wherein the polyomavirus is BK virus. 4. The method of claim 1, wherein the subject has been identified as having a JC virus infection of the central nervous system (CNS). 5. The method of claim 1, wherein the subject has been identified as having a BK virus infection of the kidney. 6. The method of claim 1, wherein the subject is undergoing, or has been undergoing, an immunomodulatory treatment. 7. The method of claim 6, wherein the immunomodulatory treatment comprises the administration of a VLA-4 antibody. 8. The method of claim 7, wherein the VLA-4 antibody is natalizumab.

Details for Patent 9,233,107

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	11/23/2004		2027-09-14